Table 5.
Biochemical data and SLEDAI score in SLE patients from atorvastatin group and from placebo group at randomization and after one year of treatment
| At randomization | After one year | P | |
|---|---|---|---|
| Atorvastatin group, n = 28 | |||
| Total cholesterol (mmol/l) | 5.1 ± 1.2 | 4.4 ± 0.7 | < 0.05 |
| LDL cholestrol (mmol/l) | 2.9 ± 1.0 | 2.3 ± 0.6 | < 0.05 |
| HDL cholesterol (mmol/l) | 1.4 ± 0.3 | 1.4 ± 0.3 | ns |
| Triglycerides (mmol/l) | 1.6 ± 0.6 | 1.2 ± 0.5 | < 0.05 |
| CRP (mg/l) | 4.4 ± 4.1 | 2.7 ± 1.7 | < 0.05 |
| ALT (IU/l) | 23.9 ± 6.7 | 22.4 ± 6.9 | ns |
| AST (IU/l) | 22.9 ± 3.7 | 31.5 ± 6.2 | ns |
| CPK (IU/l) | 70.0 ± 78.2 | 62.9 ± 47.2 | ns |
| SLEDAI | 2-20 (median 4) | 0-20 (median 4) | ns |
| Placebo group, n = 32 | |||
| Total cholesterol (mmol/l) | 4.5 ± 0.8 | 4.5 ± 0.7 | ns |
| LDL cholestrol (mmol/l) | 2.6 ± 0.8 | 2.6 ± 0.8 | ns |
| HDL cholesterol (mmol/l) | 1.4 ± 0.3 | 1.4 ± 0.3 | ns |
| Triglycerides (mmol/l) | 1.2 ± 0.5 | 1.3 ± 0.6 | ns |
| CRP (mg/l) | 4.0 ± 8.9 | 3.9 ± 5.1 | ns |
| ALT (IU/l) | 27.1 ± 8.6 | 39.1 ± 51.4* | ns |
| AST (IU/l) | 26.1 ± 6.2 | 40.2 ± 56.6* | ns |
| CPK (IU/l) | 53.2 ± 37.5 | 71.2 ± 57.2 | ns |
| SLEDAI | 0-12 (median 4) | 0-12 (median 2) | ns |
* in one patient increased ALT (248 IU/l) and AST (273 IU/l) levels were observed
CRP, C-reactive protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ns, not significant; SLE, systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.